Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Community malaria incidence study after systematic treatment of asymptomatic Plasmodium falciparum carriers with Riamet
2015-004461-85Phase 4
- Sponsor
- Novartis
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of artemether + lumefantrine in malaria and Malaria (2 arms), sponsored by Novartis. Primary endpoint: Number of symptomatic malaria episodes per person-year.
02
Drugs
artemether + lumefantrine
03
Conditions
malariaMalaria
Beyond the preview
Go deeper on 2015-004461-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004461-85.